The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study

Levomilnacipran (1S, 2R-milnacipran) is a potent and selective serotonin and norepinephrine reuptake inhibitor that is Food and Drug Administration approved for once-daily treatment of major depressive disorder in adults. Secondary and post-hoc analyses were carried out on data from a positive 10-we...

Descripción completa

Detalles Bibliográficos
Autores principales: Montgomery, Stuart A., Mansuy, Lucilla, Ruth, Adam C., Li, Dayong, Gommoll, Carl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams And Wilkins 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235391/
https://www.ncbi.nlm.nih.gov/pubmed/24172160
http://dx.doi.org/10.1097/YIC.0000000000000009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235391/
https://www.ncbi.nlm.nih.gov/pubmed/24172160
http://dx.doi.org/10.1097/YIC.0000000000000009

Ejemplares similares